hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06377748, orgStudyIdInfo id: 2023/02, briefTitle: The Effect of Facilitated-tucking and ShotBlocker on Pain Caused by Vaccination in Healthy Infants, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2024-07-30, completionDateStruct date: 2024-07-30, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Istanbul Medeniyet University, class: OTHER, descriptionModule briefSummary: This study will be investigated the effects of facilitated tucking, ShotBlocker and combined facilitated tucking and ShotBlocker methods on procedural pain, crying time and duration of the procedure during Hepatitis B vaccine administration in healthy term infants., conditionsModule conditions: Procedural Pain, conditions: Pain, Acute, conditions: Nursing Caries, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants will be assigned to experimental and control groups using block randomization method. Birth weight (2500-3000 g, 3001-3500 g, 3501 g and above), gender (male and female) and mode of delivery (vaginal and cesarean section) variables will be used for block randomization., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: DOUBLE, maskingDescription: Using the block randomization technique, participants will be divided into 4 groups. A web-based randomization list creation tool will be used to create the blocked randomization list. Control and intervention groups will be coded as A, B, C and D using the sealed envelope method. Randomization information will be kept from the researcher involved in data collection until data collection begins. The researcher will learn which group each baby is in just before the application (researcher blinding).Parents will know which group the baby is in within the scope of the research. By the nature of the sample group, babies are blind.Research data will be entered into the computer database by coding the group name as A, B, C and D, and statistical analysis will be performed using this coding (statistician blinding)., whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 144, type: ESTIMATED, armsInterventionsModule interventions name: Facilitated tucking position, interventions name: ShotBlocker, interventions name: Combined facilitated tucking and ShotBlocker, outcomesModule primaryOutcomes measure: Neonatal Infant Pain Scale, secondaryOutcomes measure: Crying time during the procedure, secondaryOutcomes measure: Procedure time, eligibilityModule sex: ALL, minimumAge: 38 Weeks, maximumAge: 42 Weeks, stdAges: CHILD, contactsLocationsModule locations facility: Istanbul Medeniyet University, city: Istanbul, state: Kadıköy, zip: 34720, country: Turkey, contacts name: Aynur Aytekin Özdemir, PhD, role: CONTACT, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06377735, orgStudyIdInfo id: CHEST-001, briefTitle: BAI-BACE for Advanced Lung Squamous Cell Carcinoma, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-12-30, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Sun Yat-sen University, class: OTHER, descriptionModule briefSummary: Bronchial arterial infusion plus bronchial arterial chemoembolization (BAI-BACE) has been reported as non-first-line therapy to treat lung cancer in many hospitals in China. BAI, which uses chemotherapeutic drugs directly injected into the tumor and achieved a high concentration in a short time to kill the tumor. Then BACE could seal off the tumor vessels. In this study, we aim to describe the efficacy and safety of BAI-BACE as non-first-line for advanced lung squamous cell carcinoma., conditionsModule conditions: Squamous Cell Carcinoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Bronchial arterial infusion, bronchial arterial chemoembolization (BACE-BAI) procedure was performed as follows: Bronchial arteriography was performed to find tumor-feeding artery. After the catheter had been inserted into the tumor-feeding artery, paclitaxel (300 mg) was infused slowly at least 30 min. BAI (bronchial arterial infusion) chemotherapy was followed by BACE (Drug-eluting beads bronchial arterial chemoembolization); the CalliSpheres loaded with cis-platinum (30 mg) were infused into the tumor-feeding arteries until stasis or near-stasis of blood flow in the vessel was observed., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 85, type: ESTIMATED, armsInterventionsModule interventions name: BAI-BACE, outcomesModule primaryOutcomes measure: Progression-Free-Survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Adverse events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Chinese PLA General hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100853, country: China, contacts name: Qunfang Zhou, MD, role: CONTACT, phone: 8619868000115, email: zhouqun988509@163.com, contacts name: Feng Duan, MD, role: CONTACT, phone: 8613910984586, email: duanfeng@vip.sina.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06377722, orgStudyIdInfo id: CABOPRE, briefTitle: Cabozantinib Treatment Prior to Cytoreductive Nephrectomy in Patients With Advanced or Metastatic Renal Cells Cancer, statusModule overallStatus: TERMINATED, startDateStruct date: 2018-11-01, primaryCompletionDateStruct date: 2022-08-09, completionDateStruct date: 2022-08-09, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Fundacion Oncosur, class: NETWORK, descriptionModule briefSummary: Phase II, multicenter, national, uncontrolled, multicenter, uncontrolled, phase II clinical trial for the evaluation of cabozantinib treatment prior to cytoreductive nephrectomy in patients with advanced or metastatic renal cell cancer candidates for primary tumor cytoreductive nephrectomy (NC)., conditionsModule conditions: Renal Cell Carcinoma Metastatic, conditions: Renal Cell Carcinoma Stage IV, conditions: Renal Cell Carcinoma Stage III, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ACTUAL, armsInterventionsModule interventions name: Cabozantinib, outcomesModule primaryOutcomes measure: Radiological response rate prior to cytoreductive nephrectomy, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Universitario Central de Asturias, city: Oviedo, state: Asturias, country: Spain, geoPoint lat: 43.36029, lon: -5.84476, locations facility: Institut Català d'Oncologia. Idibell, city: L'Hospitalet de Llobregat, state: Barcelona, country: Spain, geoPoint lat: 41.35967, lon: 2.10028, locations facility: Hospital Universitario de Valdecilla, city: Santander, state: Cantabria, country: Spain, geoPoint lat: 43.46472, lon: -3.80444, locations facility: Hospital Univeristario 12 de Octubre, city: Madrid, zip: 28041, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, locations facility: Centro Oncológico Clara Campal - HM CIOCC, city: Madrid, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, locations facility: Hospital Universitario La Paz, city: Madrid, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, locations facility: Hospital Universitario Ramón y Cajal, city: Madrid, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, locations facility: Hospital Universitario Severo Ochoa, city: Madrid, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06377709, orgStudyIdInfo id: 24CP001, briefTitle: A Mixed-methods Acceptability Study of ProACTive™ to Help Burns Patients Adjust to Changes to Appearance, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-12, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Nottingham University Hospitals NHS Trust, class: OTHER, descriptionModule briefSummary: This mixed-methods acceptability study aims to investigate whether an early acceptance and commitment therapy (ACT) based intervention called ProACTive™, aimed at supporting burns patients' adjustment to a changed appearance and preventing distress, is acceptable. This will be measured by descriptive data, questionnaire data and semi-structured interviews.Preliminary data on the potential clinical effectiveness of the intervention will also be gathered. This will be measured by scores on standardised questionnaires., conditionsModule conditions: Burn Injuries, conditions: Burns, conditions: Emotional Distress, conditions: Adjustment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: ProACTive™, outcomesModule primaryOutcomes measure: Body Esteem Scale for Adolescents and Adults - Appearance subscale (BESAA-A), secondaryOutcomes measure: Positive and Negative Affect Schedule (PANAS-GEN), secondaryOutcomes measure: Comprehensive assessment of Acceptance and Commitment Therapy processes (CompACT), secondaryOutcomes measure: Self-Compassion Scale - Short Form (SCS-SF), secondaryOutcomes measure: Helpful Aspects of Therapy Form (HAT), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06377683, orgStudyIdInfo id: XMYY-2023KY122, briefTitle: Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2025-12-30, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Xiamen University, class: OTHER, descriptionModule briefSummary: Ten to 20% of patients with prostate cancer (PC) experience progression in their disease, even after undergoing pharmaceutical or surgical castration, leading to metastatic CRPC (mCRPC). Prostate-specific membrane antigen (PSMA) is a membrane-bound glycoprotein mostly specific to the prostate. While PSMA is expressed at low levels in normal prostate, this expression increased by 100-1000-fold in PC, which makes it a favorable target for therapy. This study was designed to evaluate the safety, tolerability, and maximum tolerated dose of a long-lasting radiolabeled ligand 177Lu-Dansyl-PSMA in mCRPC patients., conditionsModule conditions: Metastatic Castration-resistant Prostate Cancer, mCRPC, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: classic 3+3 dose escalation, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: 177Lu-Dansyl-PSMA radioligand therapy, outcomesModule primaryOutcomes measure: Incidence of treatment-related adverse events (safety and tolerability), primaryOutcomes measure: To determine the maximum tolerated dose (MTD), secondaryOutcomes measure: Dosimetry, eligibilityModule sex: MALE, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Xiamen University, status: RECRUITING, city: Xiamen, state: Fujian, zip: 361003, country: China, contacts name: Haojun Chen, MD, PhD, role: CONTACT, phone: +8618659285282, email: leochen0821@foxmail.com, contacts name: Hao Fu, MD, PhD, role: CONTACT, phone: +8615959230059, email: fuhaonuclear@163.com, contacts name: Haojun Chen, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Hao Fu, MD, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 24.47979, lon: 118.08187, hasResults: False
protocolSection identificationModule nctId: NCT06377670, orgStudyIdInfo id: 38RC24.0012, briefTitle: Study of Functional and Aesthetic Outcomes After Wassel IV Thumb Duplication Surgery in Pediatric Population, With a Follow-up of at Least One Year, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2024-05-06, completionDateStruct date: 2024-05-15, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: University Hospital, Grenoble, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the functional and aesthetic outcomes in children with Wassel IV thumb duplication, conditionsModule conditions: Wassel IV Thumb Duplication, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: RETROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Wassel IV Thumb Duplication Surgery, outcomesModule primaryOutcomes measure: Functional and Aesthetic Outcomes, secondaryOutcomes measure: Comparison of Surgical Techniques, secondaryOutcomes measure: Efficacy of Skin Flap Types, secondaryOutcomes measure: Immobilization Method Analysis, secondaryOutcomes measure: Preoperative Angle Decision Model, eligibilityModule sex: ALL, minimumAge: 1 Year, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06377644, orgStudyIdInfo id: DPT/Batch-Fall19/560, briefTitle: Comparing the Efficacy of KT vs DN With Conventional Treatment for Improving QOL and Alleviating Pain in Frozen Shoulder, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-05-01, completionDateStruct date: 2024-07-05, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Superior University, class: OTHER, descriptionModule briefSummary: "Randomized control trial is our study design, we will make 2 groups group A ( 15 patients of frozen shoulder) and Group B (15 patients of frozen shoulder). we will apply interventions by this way For group A KT (kinesiology taping) will be applied on frozen shoulder patients by a professional physiotherapist or certified physiotherapist according to their pain pattern in muscles (supraspinatus, infraspinatus, teres minor, deltoid, subscapularis) with conventional physiotherapy of frozen shoulder also continues on 15 patients (group A). KT will apply twice a week for 8 weeks. We can check the results of our intervention every week by using variable tools or outcome measures, measuring pain by VAD (visual analog scale) and quality of life in the frozen shoulder by SPADI (shoulder pain and disability index) every week. And for group B Dry needling with conventional physical therapy., conditionsModule conditions: Frozen Shoulder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ACTUAL, armsInterventionsModule interventions name: Kinesio taping, interventions name: Dry Needling, outcomesModule primaryOutcomes measure: VAS, primaryOutcomes measure: SPADI, eligibilityModule sex: ALL, minimumAge: 35 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pain away Physical Therapy, city: Lahore, state: Punjab, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06377618, orgStudyIdInfo id: DPT/Batch-Fall19/556, briefTitle: Comparison Of Resistance Training And Core Strengthening Exercises Vitamin D In Postmenopausal Women With Low Back Pain, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-15, primaryCompletionDateStruct date: 2024-05-20, completionDateStruct date: 2024-06-20, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Superior University, class: OTHER, descriptionModule briefSummary: This study aims to evaluate the effectiveness of resistance training, core strengthening exercises, and vitamin D supplementation in reducing low back pain (LBP) among postmenopausal women., conditionsModule conditions: Menopausal, conditions: Pain, Low Back, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 36, type: ACTUAL, armsInterventionsModule interventions name: Resistance Training and Core Strengthening Exercises Group, interventions name: Resistance Training and Core Strengthening Exercises Group Plus Vitamin D Supplementation, outcomesModule primaryOutcomes measure: Visual Analog Scale (VAS), primaryOutcomes measure: Oswestry Disability Index (ODI), eligibilityModule sex: FEMALE, minimumAge: 50 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azra Naheed Medical College, Superior University, city: Lahore, state: Punjab, country: Pakistan, geoPoint lat: 31.558, lon: 74.35071, hasResults: False
protocolSection identificationModule nctId: NCT06377592, orgStudyIdInfo id: G22396, briefTitle: Development and Accuracy Evaluation of Gram Staining Analysis AI, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-10, primaryCompletionDateStruct date: 2027-03-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: GramEye, class: INDUSTRY, descriptionModule briefSummary: The investigators use Gram-stained specimens provided from clinical settings to develop and evaluate the accuracy of Gram staining analysis AI, conditionsModule conditions: Bacterial Infections, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: RETROSPECTIVE, enrollmentInfo count: 18000, type: ESTIMATED, armsInterventionsModule interventions name: Sample collection without intervention, outcomesModule primaryOutcomes measure: Advanced level of blood culture Gram stain analysis AI accuracy, primaryOutcomes measure: Ordinary level of blood culture Gram stain analysis AI accuracy, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Osaka University Hospital, status: RECRUITING, city: Suita, state: Osaka, zip: 5650871, country: Japan, contacts name: Go Yamamoto, role: CONTACT, geoPoint lat: 34.76143, lon: 135.51567, hasResults: False
protocolSection identificationModule nctId: NCT06377553, orgStudyIdInfo id: 2023P000955, briefTitle: PET/MRI for Evaluation of Endometriosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-03, primaryCompletionDateStruct date: 2026-05-03, completionDateStruct date: 2026-05-03, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, descriptionModule briefSummary: This study aims to determine if PET/MRI can detect endometriosis and potentially improve upon currently available non-invasive diagnostic capabilities. Specifically, the authors will investigate the ability of PET/MRI to detect and quantify endometriosis, as well as differentiate among subcategories such as inflammatory peritoneal lesions, fibrotic deep infiltrating endometriosis lesions (DIE), and ovarian endometriomas. The authors will compare \[68Ga\]CBP8 or \[18F\]-FAPI-74 PET/MRI imaging versus the current gold standard diagnostic methods, including laparoscopic surgery, clinical follow-up, and follow-up imaging., conditionsModule conditions: Endometriosis, conditions: Endometrioma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Radiotracer Injection, interventions name: Imaging, interventions name: Rectal Ultrasound Gel Injection, outcomesModule primaryOutcomes measure: Diagnostic Accuracy of PET/MR in Preoperative Endometriosis Detection, primaryOutcomes measure: Diagnostic Performance of PET/MRI vs. Conventional Imaging, secondaryOutcomes measure: Impact of [18F]-FAPI-74 and [68Ga]CBP8 PET/MRI on Diagnosis and Management in Endometriosis, secondaryOutcomes measure: Correlation of Pre-Treatment PET Uptake and Post-Treatment Response in Endometriosis, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, city: Charlestown, state: Massachusetts, zip: 02129, country: United States, contacts name: Onforio Catalano, MD, Ph.D, role: CONTACT, phone: 617-724-4030, email: ocatalano@mgh.harvard.edu, contacts name: Diandrea Galloway, role: CONTACT, phone: 617-643-1407, email: dgalloway@mgh.harvard.edu, geoPoint lat: 42.37787, lon: -71.062, hasResults: False
protocolSection identificationModule nctId: NCT06377540, orgStudyIdInfo id: 2022LS174, briefTitle: MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-01, primaryCompletionDateStruct date: 2026-09-01, completionDateStruct date: 2027-09-01, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Masonic Cancer Center, University of Minnesota, class: OTHER, descriptionModule briefSummary: This is a Phase 2 single arm study to evaluate efficacy and safety of Pembrolizumab before with BEAM ASCT followed by Pembrolizumab maintenance for 1 year. Patients will receive 200 mg Pembrolizumab Q3week starting at day - 28 before stem cell transplant until 1 year after autologous stem cell transplant., conditionsModule conditions: Autologous Stem Cell Transplant, conditions: Classic Hodgkin Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 28, type: ESTIMATED, armsInterventionsModule interventions name: Pembrolizumab, interventions name: Autologous stem cell transplant, interventions name: Carmustine, interventions name: Etoposide, interventions name: Cytarabine, interventions name: Melphalan, outcomesModule primaryOutcomes measure: Progression free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Non-relapse mortality (NRM), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Rate of Complete Metabolic Response, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False